Broad CRO Capabilities QIMA Life Sciences delivers end-to-end cellular and molecular pharmacology capabilities, spanning in silico screening, non-invasive bioanalysis, and in vitro and ex vivo assays. This enables a single partner to support preclinical programs, drug candidate development, and cosmetic ingredient testing with data suitable for regulatory and marketing claims. Target potential buyers include small-to-mid-size pharma, biotech, and cosmetics ingredient suppliers seeking Integrated preclinical services and faster decision making.

Dermatology Partner Their recent collaboration with Monasterium Laboratory and work on Atopic Dermatitis demonstrates strong skin biology expertise and non-invasive endpoints. A sales angle is to propose joint dermatology-focused studies, co-authored papers, and data packages to skincare brands, contract manufacturers, and ingredient suppliers looking to strengthen product claims and accelerate regulatory clearance.

European CRO Niche Based in France with a lean team, the company positions as a flexible, high-touch CRO ideal for EU-based projects, regulatory-aligned preclinical work, and rapid project ramp-up. This presents an opportunity to engage European cosmetics brands, biotech startups, and multinationals seeking a nimble regional partner to complement global providers.

Comprehensive Services Capabilities span discovery to preclinical development and support for drug candidates and cosmetic actives, helping clients de-risk programs and substantiate claims. Opportunities exist to offer bundled service packages, scalable capacity, and streamlined vendor management for clients looking to consolidate CRO partners.

Evidence Leadership Active publishing and collaboration signal a data-driven credibility that appeals to risk-averse clients. Propose offering access to published data, co-branded studies, and ready-to-deploy evidence packages to support regulatory submissions and marketing claims, particularly for skincare and pharmacology-focused brands.